Filings & corporate actions
- 27 OctresultsResults · Q2 FY27 · consolidated and standalone+17.1%NSE
- 21 OctshareholdingShareholding · 30 Sept 2026-1.7%NSE
- 29 JulresultsResults · Q1 FY27 · consolidated and standalone+0.5%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026-0.3%NSE
- 28 AprresultsResults · Q4 FY26 · consolidated and standalone-2.6%NSE
- 20 AprshareholdingShareholding · 31 Mar 20260.0%NSE
- 29 JanresultsResults · Q3 FY26 · consolidated and standalone-0.2%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-4.0%NSE
Reaction to results · all yearsrose on day 0 in 10 of 17 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 27 Oct 2026 | +17.1% | +19.6% | — | 50.8× |
| Q1 FY27 | 29 Jul 2026 | +0.5% | +6.4% | +9.8% | 2.7× |
| Q4 FY26 | 28 Apr 2026 | -2.6% | +11.7% | +5.1% | 1.0× |
| Q3 FY26 | 29 Jan 2026 | -0.2% | +5.3% | +4.6% | 5.7× |
| Q2 FY26 | 5 Nov 2025 | -0.5% | -3.3% | -9.8% | 4.8× |
| Q1 FY26 | 28 Jul 2025 | +0.6% | -5.3% | -8.8% | 2.9× |
| Q4 FY25 | 14 May 2025 | -4.8% | -5.8% | -8.7% | 4.1× |
| Q3 FY25 | 28 Jan 2025 | +9.5% | +3.9% | -3.6% | 2.8× |
| Q2 FY25 | 23 Oct 2024 | +17.4% | +23.2% | +14.8% | 13.2× |
| Q1 FY25 | 26 Jul 2024 | +0.1% | +4.8% | +12.6% | 6.0× |
| Q4 FY24 | 10 May 2024 | +2.5% | -0.6% | +4.5% | 9.3× |
| Q3 FY24 | 30 Jan 2024 | +3.8% | +0.3% | -6.3% | 3.0× |
| Q2 FY24 | 28 Oct 2023 | +3.2% | +17.3% | +31.9% | 6.9× |
| Q1 FY24 | 3 Aug 2023 | -2.4% | -7.1% | -1.2% | 0.8× |
| Q4 FY23 | 25 May 2023 | +5.2% | +4.4% | +15.5% | 3.4× |
| Q3 FY23 | 9 Feb 2023 | -9.9% | -7.9% | -27.2% | 5.7× |
| Q2 FY23 | 10 Nov 2022 | -1.6% | -4.8% | -7.8% | — |
| Average | +2.2% | +3.6% | +1.6% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +6.0% | +9.1% | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions PPLPHARMA settled 39.4% of its traded quantity, which is ordinary for an NSE equity. That is in line with its own one-year average of 38.7%. The latest session ranks higher than 57% of the 1,014 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.15% | -2.14% | +22.72% | +10.45% | +35.90% | +23.33% |
Valuation
Ownership
Quarterly results · consolidated
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 2,139.9 | 2,751.8 | 2,269.9 | 2,617.1 |
| YoY chg | -2.9% | -0.1% | +17.4% | +28.1% |
| Net profit (₹ Cr) | (136.2) | (8.8) | (69.4) | 5.0 |
| YoY chg | -3800.8% | -105.7% | — | — |
| Net margin | -6.4% | -0.3% | -3.1% | 0.2% |
| EPS | -1.03 | -0.07 | -0.52 | 0.04 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 34.80% · public 64.80%- Promoter
- Public and others
- Promoter
- 34.80%
- Public
- 64.80%
- Promoter change
- 0.00 pp
- Filed
- 21 Oct 2026
- FII
- 13.65%
- DII
- 14.44%
- Promoter pledged
- 0.00%
Who the public is
- Mutual funds
- 12.71%
- Insurance
- 1.23%
- FPI
- 13.65%
- Retail ≤ ₹2L
- 9.62%
- HNI > ₹2L
- 3.65%
- NRI
- 1.08%
- Bodies corporate
- 1.62%
- Shareholders
- 4,13,197
-0.47 pp QoQ
+0.21 pp QoQ
+1.14 pp QoQ
-1.40 pp QoQ
+0.13 pp QoQ
-0.01 pp QoQ
+0.48 pp QoQ
-10.4% QoQ
Major holders
As of 30 Sept 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| The Sri Krishna Trust (through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A. Piramal) | Promoter · Other | 26.51% | 35.29Cr |
| Ca Alchemy Investments | Corporate | 17.93% | 23.87Cr |
| Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund | Mutual fund | 5.65% | 7.52Cr |
| V3 Designs LLP | Promoter · Corporate | 3.23% | 4.30Cr |
| PRL Realtors LLP | Promoter · Corporate | 2.99% | 3.98Cr |
| East Bridge Capital Master Fund I Ltd | FPI | 2.00% | 2.66Cr |
| Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund | Mutual fund | 1.56% | 2.08Cr |
| Indiahold Limited | Corporate | 1.30% | 1.73Cr |
| Piramal Welfare Trust | Promoter · Other | 0.79% | 1.06Cr |
| Semplice Corporate Solutions Private Limited | Promoter · Corporate | 0.67% | 89.31L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Dividends
| Financial year | Payments | Declared | Adjusted |
|---|---|---|---|
| FY2025-26 | 1 | ₹0.14 | ₹0.14 |
| FY2024-25 | 1 | ₹0.11 | ₹0.11 |
| Ex-date | Record date | Declared | Adjusted |
|---|---|---|---|
| 16 Jul 2025 | — | ₹0.14 | ₹0.14 |
| 12 Jul 2024 | — | ₹0.11 | ₹0.11 |
Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.
Bulk & block deals · 20 Feb 2025
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 20 Feb 2025 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 68.57L | 219.88 | ₹150.8Cr |
| 20 Feb 2025 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 68.57L | 219.70 | ₹150.6Cr |
| 16 Jun 2023 | Sell · bulk | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 1.06Cr | 94.48 | ₹99.9Cr |
| 16 Jun 2023 | Buy · bulk | THE VANGUARD GROUP INC AC VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND | 62.03L | 94.71 | ₹58.7Cr |
| 1 Nov 2022 | Sell · bulk | BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L | 1.41Cr | 158.88 | ₹223.5Cr |
| 1 Nov 2022 | Buy · bulk | BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L | 3.10L | 158.49 | ₹4.9Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.
Exchange surveillance
- Zero EPS (4 quarters) · since 12 Jan 2026 — Zero EPS over the last four quarters.
Price band: 20% · not in the F&O ban · 0.0% of the market-wide position limit used.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes · MWPL.
Every stock on this session →Futures & options · 28 Apr 2026
CSVLong unwinding — price down as positions closed — longs exiting.
- Futures OI
- 20.37L
- OI change
- -44.01%
- Basis
- -0.15%
- Rollover
- 0.0%
- PCR (OI)
- 1.01
- PCR (volume)
- 0.75
- Front settle
- 164.47
- Lot size
- 2,625
- Futures volume
- 1.6K
- Futures trades
- 1,406
- Futures value
- ₹67.7Cr
- Sessions shown
- 226
₹33.5Cr
shares
contracts
Open interest is in shares (index units for an index), summed over every expiry; volume, trades and traded value too. Settle and lot size are the front future’s. Buildup compares the close’s direction with the change in futures OI across the contracts still open, so an expiring contract does not read as unwinding. Scan it with pattern is long_buildup.
Financials · quarterly statement
| Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,958.6 | 2,552.4 | 1,951.1 | 2,241.8 | 2,204.2 | 2,754.1 | 1,933.7 | 2,043.7 | 2,139.9 | 2,751.8 | 2,269.9 | 2,617.1 | |
| Other income | 61.5 | 26.4 | 19.5 | 61.1 | 12.1 | 42.0 | 58.4 | 65.6 | 43.2 | 46.1 | 89.4 | 35.9 | |
| Total income | 2,020.1 | 2,578.7 | 1,970.7 | 2,302.9 | 2,216.4 | 2,796.1 | 1,992.1 | 2,109.3 | 2,183.1 | 2,797.8 | 2,359.3 | 2,653.0 | |
| Total expenses | 1,982.4 | 2,332.8 | 2,038.2 | 2,200.0 | 2,166.6 | 2,539.5 | 2,110.4 | 2,170.3 | 2,246.1 | 2,592.6 | 2,386.4 | 2,589.1 | |
| └ Finance costs | 105.9 | 114.2 | 107.0 | 107.6 | 103.3 | 103.7 | 86.2 | 82.4 | 89.2 | 83.0 | 88.1 | 87.6 | |
| └ Depreciation | 186.3 | 196.1 | 184.6 | 192.2 | 196.8 | 242.8 | 197.3 | 202.8 | 212.7 | 218.4 | 223.6 | 233.2 | |
| Profit before tax | 5.4 | 215.4 | (67.5) | 102.9 | 49.8 | 256.6 | (97.6) | (61.0) | (104.1) | 29.4 | (27.0) | 63.9 | |
| Tax expense | 9.3 | 126.2 | 43.6 | 97.5 | 63.1 | 119.3 | 2.7 | 53.0 | 42.3 | 51.8 | 61.9 | 76.6 | |
| Net profit | 10.1 | 101.3 | (88.6) | 22.6 | 3.7 | 153.5 | (81.7) | (99.2) | (136.2) | (8.8) | (69.4) | 5.0 | |
| EPS | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.62 | -0.75 | -1.03 | -0.07 | -0.52 | 0.04 | |
| Net margin | 0.52% | 3.97% | -4.54% | 1.01% | 0.17% | 5.57% | -4.23% | -4.85% | -6.36% | -0.32% | -3.06% | 0.19% | |
| PBT margin | 0.28% | 8.44% | -3.46% | 4.59% | 2.26% | 9.32% | -5.05% | -2.98% | -4.87% | 1.07% | -1.19% | 2.44% | |
| Tax rate | 170.98% | 58.58% | — | 94.82% | 126.87% | 46.50% | — | — | — | 176.11% | — | 119.89% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 27 Oct 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 14,522.6 | 14,775.7 | 15,311.8 | 15,241.7 | 15,677.6 | 16,189.4 | 17,965.0 | 18,537.2 | |
| Current assets | 4,835.5 | 4,954.0 | 5,464.5 | 5,381.7 | 5,797.0 | 5,953.0 | 7,191.7 | 7,253.7 | |
| └ Cash & equivalents | 195.6 | 251.5 | 356.8 | 270.3 | 369.0 | 499.4 | 1,199.9 | 545.0 | |
| └ Other bank balances | 112.0 | 284.5 | 125.7 | 127.7 | 132.5 | 22.1 | 23.8 | 23.6 | |
| └ Current investments | 427.1 | 59.1 | 144.7 | 10.4 | 19.6 | 222.5 | 131.8 | 261.4 | |
| └ Trade receivables | 1,799.3 | 1,743.4 | 2,134.4 | 1,827.1 | 2,349.5 | 1,984.6 | 2,157.7 | 2,253.7 | |
| └ Inventories | 1,681.4 | 2,060.5 | 2,175.9 | 2,447.4 | 2,312.7 | 2,742.8 | 3,064.4 | 3,294.8 | |
| Total equity | 6,773.5 | 7,757.9 | 7,911.4 | 7,907.2 | 8,125.5 | 8,073.8 | 8,162.6 | 8,164.7 | |
| └ Attributable to owners | 6,773.5 | 7,757.9 | 7,911.4 | 7,907.2 | 8,125.5 | 8,073.8 | 8,162.6 | 8,142.2 | |
| └ Non-controlling interest | — | 0.0 | — | — | 0.0 | — | 0.0 | 22.5 | |
| └ Share capital | 1,193.3 | 1,323.0 | 1,323.0 | 1,323.1 | 1,324.4 | 1,325.5 | 1,327.2 | 1,328.4 | |
| Borrowings | 5,504.8 | 4,404.0 | 4,558.9 | 4,643.1 | 4,720.3 | 4,715.4 | 5,495.5 | 5,665.3 | |
| └ Current | 2,121.2 | 1,542.9 | 2,075.1 | 3,108.1 | 1,506.2 | 1,398.6 | 1,195.5 | 1,211.7 | |
| └ Non-current | 3,383.5 | 2,861.1 | 2,483.8 | 1,535.0 | 3,214.1 | 3,316.9 | 4,300.0 | 4,453.6 | |
| Trade payables | 1,192.7 | 1,460.7 | 1,538.4 | 1,335.7 | 1,533.8 | 1,828.2 | 2,479.1 | 2,734.8 | |
| Current liabilities | 3,843.1 | 3,596.6 | 4,369.3 | 5,237.3 | 3,766.3 | 4,159.7 | 4,758.3 | 5,158.5 | |
| Total liabilities | 7,749.1 | 7,017.8 | 7,400.4 | 7,334.6 | 7,552.1 | 8,115.6 | 9,802.4 | 10,372.5 | |
| Net debt | 4,770.1 | 3,808.9 | 3,931.6 | 4,234.7 | 4,199.3 | 3,971.4 | 4,140.1 | 4,835.3 | |
| Debt / equity | 0.81 | 0.57 | 0.58 | 0.59 | 0.58 | 0.58 | 0.67 | 0.69 | |
| Current ratio | 1.26 | 1.38 | 1.25 | 1.03 | 1.54 | 1.43 | 1.51 | 1.41 |
Cash flow, year to date
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 483.9 | 508.3 | 1,004.5 | 184.7 | 892.3 | 889.8 | 1,652.6 | 390.9 | |
| └ Capex | (964.8) | (323.1) | (712.0) | (260.2) | (664.4) | (433.2) | (890.0) | (858.7) | |
| Free cash flow | (480.9) | 185.1 | 292.5 | (75.4) | 227.9 | 456.5 | 762.6 | (467.8) | |
| Investing cash flow | (1,338.8) | (107.2) | (434.0) | (74.4) | (477.5) | (468.3) | (826.0) | (970.5) | |
| Financing cash flow | 817.8 | (386.5) | (422.4) | (262.5) | (440.8) | (361.0) | (39.0) | (131.3) | |
| └ Dividends paid | (67.0) | 0.0 | 0.0 | (14.5) | (14.5) | (18.6) | (18.6) | 0.0 | |
| └ Buybacks | 0.0 | (13.2) | (14.1) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | (37.1) | 14.6 | 148.2 | (157.5) | (26.0) | 60.5 | 793.9 | (686.1) |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →PPLPHARMA at a glance
- PPLPHARMA closed at ₹239.3 on 20 Nov 2026, -0.15% on the day, +23.3% over one year, 5.8% below its 52-week high of ₹253.9.
- Delivery was 45.6% of traded quantity on 20 Nov 2026, the 57th percentile of its own 1,014 sessions with a reading (20-session average 39.4%, 1-year average 38.7%).
- Market capitalisation is ₹31,859 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-1.57).
- Q2 FY27 results (consolidated, filed 27 Oct 2026): revenue ₹2,617 crore (+28.1% year on year), net profit ₹5 crore; the price moved +17.1% on the first session after.
- Promoters held 34.80% at 30 Sept 2026, unchanged on the previous filing.
- Q3 FY27 results are expected between 28 Jan 2027 and 9 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Sector history
- to 16 Aug 2026Index industry · Healthcare
- from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
NSE’s own classification, by the snapshot it changed on.
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
- TOTORNTPHARMTorrent Pharmaceuticals Limited4,689.50+1.70%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE